Presented on April 1st, 2022.
Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions. Click here to learn more about Dyne Therapeutics.
Dr. Ashish Dugar, SVP and Global Head of Medical Affairs at Dyne Therapeutics, will present an overview of Dyne’s DM1 candidate, DYNE-101, including preclinical data and plans for the upcoming clinical trial. Q&A hosted by Molly White, Vice President, Medical Communications & Advocacy.